Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

Lippi, Giuseppe; Favaloro, Emmanuel J.; Sanchís-Gomar, Fabián

doi:10.1016/j.ejim.2020.04.036

Cited by 9 publications

(6 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent phase II trials, a once weekly injection produced an impressive 80% decrease in Lp(a) levels, with lowering of Lp(a) levels to <50 mg/dL in 90% of patients. 30,31 Other treatment modalities 32 anticipated to begin phase II trials are in the pipeline.…”

Section: Lp(a) Screening Guidelinesmentioning

confidence: 99%

Should Lipoprotein(a) be Measured in Youth?

Kohn

Ashraf

Wilson

2021

The Journal of Pediatrics

View full text Add to dashboard Cite

Section: Lp(a) Screening Guidelinesmentioning

confidence: 99%

Should Lipoprotein(a) be Measured in Youth?

Kohn

Ashraf

Wilson

2021

The Journal of Pediatrics

View full text Add to dashboard Cite

“…Promising therapies for Lp(a) include antisense oligonucleotides that selectively bind mRNA coding for apolipoprotein (a). 38 However, its potential role in the treatment of PAD is still unclear and clinical studies will be necessary.…”

Section: Discussionmentioning

confidence: 99%

Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review

Masson

Lobo²,

Barbagelata

et al. 2022

Vasc Med

View full text Add to dashboard Cite

Background: Despite strong association of elevated lipoprotein (a) (Lp(a)) levels with incident coronary and cerebrovascular disease, data for incident peripheral artery disease (PAD) are less robust. The main objective of the present systematic review was to analyze the association between elevated Lp(a) levels and PAD outcomes. Methods: This systematic review was performed according to PRISMA guidelines. A literature search was performed to detect randomized clinical trials or observational studies with a cohort design that evaluated the association between Lp(a) levels and PAD outcomes. Results: Fifteen studies including 493,650 subjects were identified and considered eligible for this systematic review. This systematic review showed that the vast majority of the studies reported a significant association between elevated Lp(a) levels and the risk of PAD outcomes. The elevated Lp(a) levels were associated with a higher risk of incident claudication (RR: 1.20), PAD progression (HR: 1.41), restenosis (HR: 6.10), death and hospitalization related to PAD (HR: 1.37), limb amputation (HR: 22.75), and lower limb revascularization (HR: 1.29 and 2.90). In addition, the presence of elevated Lp(a) values were associated with a higher risk of combined PAD outcomes, with HRs in a range between 1.14 and 2.80, despite adjusting for traditional risk factors. Heterogeneity of results can be explained by different patient populations studied and varying Lp(a) cut-off points of Lp(a) analyzed. Conclusion: This systematic review suggests that evidence is available to support an independent positive association between Lp(a) levels and the risk of future PAD outcomes. PROSPERO Registration No.: 289253.

show abstract

“…Lipoprotein (a) or Lp (a) is a lipoprotein moiety that consists of core lipoprotein molecule, containing apolipoprotein B (apo-B100), to which a glycoprotein of variable molecular weight, apolipoprotein (a) [apo(a)], is covalently attached via a cysteine-cysteine disulfide bond 5 , 6 . By binding LDL, calcium, and other components into an atherosclerotic plaque on the walls of blood arteries, Lp (a) is hypothesised to speed up the development of atherosclerosis 7 .…”

Section: Introductionmentioning

confidence: 99%

“…The length of time it takes to modify larger apo(a) isoforms is determined by the size of the apo(a) isoform. As a result, larger apo(a) molecules are produced at a slower rate per unit of time, resulting in lower Lp (a) plasma concentrations 6 , 12 . Plasma Lp (a) concentrations appear to be regulated by synthesis rather than catabolism, according to kinetic studies.…”

Section: Introductionmentioning

confidence: 99%

“…Almost 80% of strokes are ischemic stroke (IS) and 15-20% are haemorrhagic stroke (HS) in origin 2,3 . According to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification; IS has been categorised according to the presumed etiological mechanism into five groups: large artery atherosclerosis (LAA), small vessel disease (SVD), cardioembolic disease (CE), other determined etiology (ODE), and undetermined etiology (UDE) 4 .Lipoprotein (a) or Lp (a) is a lipoprotein moiety that consists of core lipoprotein molecule, containing apolipoprotein B (apo-B100), to which a glycoprotein of variable molecular weight, apolipoprotein (a) [apo(a)], is covalently attached via a cysteine-cysteine disulfide bond 5,6 . By binding LDL, calcium, and other components into an atherosclerotic plaque on the walls of blood arteries, Lp (a) is hypothesised to speed up the development of atherosclerosis 7 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis

Kumar

Swarnkar

Misra

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The role of lipoprotein-A [Lp (a)] as a risk factor for stroke is less well documented than for coronary heart disease. Hence, we conducted a systematic review and meta-analysis for the published observational studies in order to investigate the association of Lp (a) levels with the risk of stroke and its subtypes. In our meta-analysis, 41 studies involving 7874 ischemic stroke (IS) patients and 32,138 controls; 13 studies for the IS subtypes based on TOAST classification and 7 studies with 871 Intracerebral hemorrhage (ICH) cases and 2865 control subjects were included. A significant association between increased levels of Lp (a) and risk of IS as compared to control subjects was observed (standardized mean difference (SMD) 0.76; 95% confidence interval (CIs) 0.53–0.99). Lp (a) levels were also found to be significantly associated with the risk of large artery atherosclerosis (LAA) subtype of IS (SMD 0.68; 95% CI 0.01–1.34) as well as significantly associated with the risk of ICH (SMD 0.65; 95% CI 0.13–1.17) as compared to controls. Increased Lp (a) levels could be considered as a predictive marker for identifying individuals who are at risk of developing IS, LAA and ICH.

show abstract

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

Cited by 9 publications

References 62 publications

Should Lipoprotein(a) be Measured in Youth?

Should Lipoprotein(a) be Measured in Youth?

Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review

Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis

Contact Info

Product

Resources

About